ATL, frankly $250K is an inexpensive treatment for curing cancer, even in one year, but certainly for three years of treatment, but I'd be surprised if that's how it will be paid. I certainly don't know how it will be done, but I'm of the belief that treatment will be started with a greater payment up front for making the vaccine and the first dose of it, beyond that I believe each dose will bring in the same price.
If as expected Advent and CRL become the CDMO for providing DCVax-L throughout the world their relationship with NWBO could be structured many different ways. One way could have them paid only once per patient, when the vaccine was originally made. Another would have them being paid every time vaccine was dispensed for use by the patient. My point is, it will be between NWBO and the CDMO's to define how this is to be done, likewise how they're to pay for the lease of the EDEN units which are anticipated to ultimately be making all the vaccine.
Of course there are other possibilities, partnerships where the partner takes on this responsibility, actually going it alone with the EDEN's, etc. Time will tell what course they intend to take. Regardless of the course, on regulatory approval NWBO will achieve tremendous financial success and if they're not bought out, could become one of the giant biotech's.
I'm all for bringing down the cost of healthcare, but I believe it should be done by bringing the cost of product development down. It shouldn't take decades and hundreds of millions, or more, to take a product from genesis to approval. Until that changes, developers of products need to continue to be compensated for what they've spent in time and money. I don't know what the list price for DCVax-L will be, but whatever it is, for those who receive its maximum benefit, it will be a steal. Of course not all will get that maximum benefit, but that's true of essentially all healthcare products.
Gary
Bullish
